Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$97.46

7.96 (8.89%)

16:20
01/06/19
01/06
16:20
01/06/19
16:20

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

Galapagos NV expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with '1690 in IPF. NOVESA is a double-blind, placebo-controlled Phase 2a trial evaluating the efficacy, safety and PK/PD of '1690 in patients with systemic sclerosis. NOVESA is planned to recruit 30 patients with diffuse cutaneous SSc, an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases. One of the most visible manifestations is hardening of the skin. In diffuse cutaneous SSc, skin thickening affects several body areas, and patients have a higher risk of developing fibrosis of various internal organs, such as the lung. Currently, there are no approved drugs for this disease. SSc affects approximately 90,000 patients in the US and Europe, with a predominance of female patients. The primary endpoint of NOVESA is the modified Rodnan skin score at 24 weeks. mRRS measures the skin thickness as a surrogate measure of disease severity and mortality, with an increase in thickness associated with involvement of internal organs and increased mortality. Secondary objectives and exploratory endpoints include FVC, HRCT, quality of life as measured by QoL-Q, and CRISS, a SSc disease composite score.

  • 07

    Jan

  • 22

    Feb

  • 26

    Apr

GLPG Galapagos NV
$97.46

7.96 (8.89%)

12/13/18
FBCO
12/13/18
UPGRADE
FBCO
Outperform
Galapagos NV upgraded to Outperform from Neutral at Credit Suisse
12/13/18
12/13/18
UPGRADE

Outperform
Galapagos NV upgraded to Outperform at Credit Suisse after removal of headwinds
As previously reported, Credit Suisse analyst Vamil Divan upgraded Galapagos NV (GLPG) to Outperform from Neutral following removal of headwinds and given the multiple assets that the company now has in mid-late stage development. Among the headwinds were the cystic fibrosis franchise, which he had concern about and is being run by AbbVie (ABBV), and clarity on the U.S. filing timelines for lead asset filgotinib, the analyst notes. Divan also raised his price target on Galapagos NV shares to EUR130 from EUR90.
12/19/18
CANT
12/19/18
INITIATION
Target $130
CANT
Overweight
Galapagos NV initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle started Galapagos NV with an Overweight rating and $130 price target. 2019 will be the year that filgotinib could differentiate itself among the JAK inhibitors, Merle tells investors in a research note. The analyst thinks filgotinib's potential is underappreciated and that upside could come from Phase 3 readouts that will show its profile.
12/19/18
CANT
12/19/18
NO CHANGE
Target $92
CANT
Overweight
Gilead price target raised to $92 from $88 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Gilead Sciences (GILD) to $92 after her firm increased its peak 2027 filgotinib sales estimate from $2.75B to $4.0B. Gilead books revenues in the U.S. and ~20% of sales are outside the U.S., so filgotinib is a key pipeline product not only for Galapagos NV (GLPG), but also for Gilead, Young tells investors in a research note. She reiterates an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

ORTX

Orchard Therapeutics

$13.00

0.2 (1.56%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Hot Stocks
Orchard Therapeutics announces OTL-300 data published »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$62.51

1.99 (3.29%)

07:47
01/22/19
01/22
07:47
01/22/19
07:47
Hot Stocks
Jacobs Engineering awarded $93M contract for California WaterFix program »

Jacobs has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 19

    Feb

STT

State Street

$71.19

0.07 (0.10%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Recommendations
State Street analyst commentary  »

State Street price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDFN

Redfin

$18.49

0.48 (2.67%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Redfin rating change  »

Redfin downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

, TK

Teekay Corp.

$3.74

0.28 (8.09%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Teekay Offshore Partners, Teekay Corp. rating change  »

Teekay Offshore Partners…

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

TK

Teekay Corp.

$3.74

0.28 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OZK

Bank OZK

$32.07

4.47 (16.20%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Bank OZK analyst commentary  »

Bank OZK price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$333.74

3.69 (1.12%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

TGTX

TG Therapeutics

$4.51

0.095 (2.15%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Hot Stocks
TG Therapeutics announces breakthrough therapy designation for umbralisib »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXP

Lexington Realty

$9.01

0.01 (0.11%)

07:44
01/22/19
01/22
07:44
01/22/19
07:44
Upgrade
Lexington Realty rating change  »

Lexington Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$6.83

-0.19 (-2.71%)

07:43
01/22/19
01/22
07:43
01/22/19
07:43
Hot Stocks
Cytokinetics announces FDA feedback for potential reldesemtiv program »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$22.94

0.99 (4.51%)

, FISV

Fiserv

$77.83

3.23 (4.33%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Downgrade
First Data, Fiserv rating change  »

First Data downgraded to…

FDC

First Data

$22.94

0.99 (4.51%)

FISV

Fiserv

$77.83

3.23 (4.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

SAIC

SAIC

$66.03

0.38 (0.58%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Conference/Events
SAIC management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

PSEC

Prospect Capital

$6.74

0.04 (0.60%)

07:41
01/22/19
01/22
07:41
01/22/19
07:41
Downgrade
Prospect Capital rating change  »

Prospect Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOG

GasLog

$18.21

0.7 (4.00%)

07:40
01/22/19
01/22
07:40
01/22/19
07:40
Downgrade
GasLog rating change  »

GasLog downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

OFG

OFG Bancorp

$18.14

0.19 (1.06%)

07:40
01/22/19
01/22
07:40
01/22/19
07:40
Earnings
OFG Bancorp reports Q4 EPS 45c, consensus 42c »

Net income available to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 07

    Feb

  • 27

    Feb

07:40
01/22/19
01/22
07:40
01/22/19
07:40
General news
Treasury Market Outlook: Treasury yields are lower in risk-off trades »

Treasury Market Outlook:…

TPC

Tutor Perini

$18.33

0.5 (2.80%)

07:39
01/22/19
01/22
07:39
01/22/19
07:39
Downgrade
Tutor Perini rating change  »

Tutor Perini downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$5.53

-0.12 (-2.12%)

07:38
01/22/19
01/22
07:38
01/22/19
07:38
Hot Stocks
Translate Bio announces clinical hold on MRT5201 IND application from FDA »

Translate Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSY

Insys Therapeutics

$4.42

-0.25 (-5.35%)

07:37
01/22/19
01/22
07:37
01/22/19
07:37
Initiation
Insys Therapeutics initiated  »

Insys Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCM

R1 RCM

$8.32

0.16 (1.96%)

07:37
01/22/19
01/22
07:37
01/22/19
07:37
Initiation
R1 RCM initiated  »

R1 RCM initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$49.23

0.76 (1.57%)

07:36
01/22/19
01/22
07:36
01/22/19
07:36
Recommendations
Intel analyst commentary  »

Intel Q4 results should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

ONCS

OncoSec

$0.71

0.0134 (1.93%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Conference/Events
OncoSec management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

D

Dominion

$68.75

-0.15 (-0.22%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Downgrade
Dominion rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 10

    Feb

UBSH

Union Bankshares

$32.50

0.14 (0.43%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Earnings
Union Bankshares reports Q4 ex-items EPS 70c, consensus 68c »

Q4 net charge-offs were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 11

    Feb

JD

JD.com

$23.25

1.12 (5.06%)

, INTC

Intel

$49.23

0.76 (1.57%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

JD

JD.com

$23.25

1.12 (5.06%)

INTC

Intel

$49.23

0.76 (1.57%)

WYNN

Wynn Resorts

$115.19

0.94 (0.82%)

NKE

Nike

$80.45

1.33 (1.68%)

CRON

Cronos Group

$14.89

1.25 (9.16%)

MGM

MGM Resorts

$28.55

0.83 (2.99%)

AUY

Yamana Gold

$2.31

-0.12 (-4.94%)

UAA

Under Armour

$20.50

0.47 (2.35%)

I

Intelsat

$21.15

-1.26 (-5.62%)

APC

Anadarko

$48.68

0.61 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 06

    Feb

  • 10

    Feb

  • 13

    Feb

  • 21

    Feb

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.